Epristeride
Title: Epristeride
CAS Registry Number: 119169-78-7
CAS Name: (17b)-17-[[(1,1-Dimethylethyl)amino]carbonyl]androsta-3,5-diene-3-carboxylic acid
Additional Names: 17b-(N-tert-butylcarboxamido)androsta-3,5-diene-3-carboxylic acid
Manufacturers' Codes: SKF-105657
Molecular Formula: C25H37NO3
Molecular Weight: 399.57
Percent Composition: C 75.15%, H 9.33%, N 3.51%, O 12.01%
Literature References: 5a-Reductase inhibitor. Prepn and in vitro activity: D. A. Holt et al., EP 289327; eidem, US 4910226 and US 5017568 (1988, 1990, 1991 all to SmithKline Beecham); D. A. Holt et al., J. Med. Chem. 33, 943 (1990). Pharmacology: J. C. Lamb et al., Endocrinology 130, 685 (1992). Antitumor effects in rats: J. C. Lamb et al., Prostate 21, 15 (1992). Mechanism of action study: M. A. Levy et al., Biochemistry 29, 2815 (1990). HPLC determn in human plasma: V. K. Boppana et al., J. Chromatogr. 631, 251 (1993).
Properties: White crystals from ethyl acetate, mp 242-249°. pK 4.8.
Melting point: mp 242-249°
pKa: pK 4.8
Therap-Cat: Treatment of benign prostatic hypertrophy.
Keywords: Antiprostatic Hypertrophy; 5a-Reductase Inhibitor.

Others monographs:
SquillCetoximeSodium Tetradecyl SulfateN,N-Dimethylacetamide
CAPSBromosuccinic AcidHypochlorous AcidGoserelin
4-Amino-3-hydroxybutyric Acid5-Fluoroorotic AcidBorneolChloraminophenamide
Aluminum Lithium HydridePeanutDiprenorphineRaubasine
©2016 DrugLead US FDA&EMEA